secwatch.observer — SEC 8-K summary
======================================

Issuer:     Insight Molecular Diagnostics Inc. (IMDX)
CIK:        0001642380
Form:       8-K
Filed at:   2026-08-10T20:10:27+00:00
Accession:  0001493152-26-036863
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

iMDx reports Q2 net loss of $11.3M; FDA issues Additional Information Request for GraftAssureDx
--------------------------------------------------------------------------------

- Q2 2026 revenue ~$239K; gross profit $157K (65.7% margin); net loss $11.3M ($0.31/share); adjusted net loss $8.3M ($0.23/share).
- FDA issued Additional Information Request on GraftAssureDx; company must respond within 180 days; expects one more FDA meeting before Q4.
- Medicare LCD (MolDX, July 16) expands dd-cfDNA surveillance coverage, doubling testing to 4x/yr in years 2-3 post-kidney transplant.
- Head-to-head data published in Clinical Chemistry: 99.2% agreement vs leading NGS competitor; CM-Score doubles PPV to 81% vs 54% benchmark.
- R&D expenses $4.5M (-9% sequentially); company remains pre-revenue awaiting FDA authorization for kitted GraftAssureDx.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1642380/000149315226036863/0001493152-26-036863-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1642380/000149315226036863/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-036863

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer